secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017402
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q2 revenue $13.8M (+2% YoY); net loss $2.2M; lowers FY22 guidance
------------------------------------------------------------------------

- Total revenue $13.8M, up 2% YoY; net loss $2.2M ($0.14/sh) vs net income $1.4M ($0.09) prior year due to one-time PPP loan forgiveness.
- Gross margin 45.6% vs 45.5% YoY; operating expenses rose 16% to $8.4M on sales/marketing and R&D investment.
- Cyclo G6 probe sales of 15,000 (-6% YoY); full-year probe guidance cut to 61k-63k from prior 67k-70k.
- Revenue guidance lowered to $56M-58M from $57M-59M, reflecting 4%-8% growth; management cites macro headwinds and COVID surge.
- Received NMPA clearance to market Cyclo G6 platform in China; sold initial systems and conducted clinical launch with 70 physicians.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017022017402/0000950170-22-017402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017022017402/irix-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer